SCHEMBL23988588

SCHEMBL23988588

Cc1c(OCC(F)(F)F)ccnc1CC(O)c1nc2cc(OC(F)(F)F)ccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
RAB9A P51151 2/20 0.46
ATP4A P20648 7/20 0.44
ATP4B P51164 7/20 0.44
ATP1A1 P05023 5/20 0.44
ATP1B1 P05026 5/20 0.44
ATP1A3 P13637 5/20 0.44
ATP1B2 P14415 5/20 0.44
ATP1A2 P50993 5/20 0.44
ATP1B3 P54709 5/20 0.44
FXYD2 P54710 5/20 0.44
ATP1A4 Q13733 5/20 0.44
KMT2A Q03164 4/20 0.44
WDR5 P61964 3/20 0.44
MAPT P10636 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988401 0.92 CYP3A4 (0.45) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988402 0.92 NPC1 (0.46) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988586 0.92 KMT2A (0.41) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988445 0.91 ATP4A (0.47) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988411 0.89 KMT2A (0.47) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988262 0.85 CYP2C9 (0.63) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988500 0.85 SARM1 (0.45) CYP1A2CYP3A4CYP2C9CYP2C19ATP4A
SCHEMBL23988489 0.83 RUNX1 (0.51) CYP3A4CYP2C9ATP4AATP4BATP1A1
SCHEMBL23988274 0.83 CYP2C9 (0.46) NPC1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23988413 0.81 ATP4A (0.43) CYP1A2CYP3A4CYP2C9CYP2C19ATP4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202796-A1 CXCL10 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-06-30 US disclosed
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202796-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 NPC1 1955/4885CYP1A2 4464/4885CYP3A4 4635/4885
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 NPC1 1955/4885CYP1A2 4464/4885CYP3A4 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.